Under the terms of the Context License Agreement, BioAtla granted Context an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies
BioAtla, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BCAB-DEBT-8089
Warrants outstanding: 59.5
90%
xbrl warrant detail from xbrl 2026-03-31.
BCAB-DEBT
Debt stack $6.1M
90%
Market cache reports total debt of $6.1M.
BioAtla, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioAtla, Inc..
BioAtla, Inc. Ownership
Holder
Name
Confidence
Evidence
BCAB-OWNER-ACORN-CAPITAL-ADVISORS-LLC
ACORN CAPITAL ADVISORS, LLC
90%
13F overlay lists ACORN CAPITAL ADVISORS, LLC as top holder; 35 tracked holders.
BioAtla, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.